AZD2066 Neuropathic Pain - Mechanical Hypersensitivity (NP-MH)

AstraZeneca

Status and phase: Terminated; Phase 2

Conditions: Neuropathic Pain; Mechanical Hypersensitivity

Treatments: Drug: AZD2066; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00939094

D0475C00016

Details and patient eligibility

About

The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only cause a little pain.

Enrollment: 87 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed consent prior to any study specific procedures.
• Male or non-fertile females
• Painful symptoms due to neuropathic pain for a period of 3 months to 5 years, associated with mechanical allodynia and/or punctate hyperalgesia.

Exclusion criteria

• Other pain that may confound assessment of neuropathic pain.
• Diagnosis of any severe neurological disease.
• History of significant psychiatric disease/condition and/or history of psychotic disorders among first degree relatives.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

87 participants in 2 patient groups, including a placebo group

A

Experimental group

Treatment:

Drug: AZD2066

B

Placebo Comparator group

Treatment:

Drug: Placebo